NKARTA, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 2nd, 2020 • Nkarta, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of [________], 2020 and is between Nkarta, Inc., a Delaware corporation (the “Company”), and [______________] (“Indemnitee”).
NKARTA, INC. COMMON STOCK SALES AGREEMENTSales Agreement • August 12th, 2021 • Nkarta, Inc. • Pharmaceutical preparations • New York
21,010,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,000,031 Shares of Common Stock NKARTA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2024 • Nkarta, Inc. • Pharmaceutical preparations • New York
BRITANNIA OYSTER POINT I LEASELease • July 14th, 2021 • Nkarta, Inc. • Pharmaceutical preparations • California
This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
NKARTA, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 27, 2019Investors’ Rights Agreement • June 19th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of August, 2019, by and among Nkarta, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees who become parties to this Agreement in accordance with Section 6.9 hereof, each an “Investor” and together the “Investors”).
LEASE HCP LIFE SCIENCE REIT, INC., a Maryland corporation, as Landlord, and NKARTA, INC., a Delaware corporation, as Tenant.Lease Agreement • April 20th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (“Landlord”), and NKARTA, INC., a Delaware corporation (“Tenant”).
SECOND AMENDMENT TO LEASELease • August 11th, 2022 • Nkarta, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LEASE (this "Second Amendment") is made and entered into as of the 11th of August, 2022, by and between HCP BTC, LLC, a Delaware limited company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
FOURTH AMENDMENT TO LEASELease • October 22nd, 2021 • Nkarta, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of October 19th, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
Notice of Grant of Stock Option and Terms and Conditions of Stock OptionStock Option Agreement • August 20th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • Delaware
Effective [___________] (the “Award Date”), you (the “Grantee”) have been granted a nonqualified stock option (the “Option”) to buy [________] shares1 of Common Stock of Nkarta, Inc. (the “Corporation”) at a price of $[_______] per share1 (the “Exercise Price”).
Amendment No. 3 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • August 13th, 2024 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 3 to the Research Collaboration Agreement (the “Amendment”) is entered into as of April 3, 2024 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022 and Amendment No. 2 to the Research Collaboration Agreement entered into as of March 8, 2023 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
FIRST AMENDMENT TO LEASELease • April 20th, 2020 • Nkarta, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE (this “First Amendment”) is made and entered into as of April 24, 2019, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (“Landlord”), and NKARTA, INC., a Delaware corporation - (“Tenant”).
SECOND AMENDMENT TO LEASELease • June 19th, 2020 • Nkarta, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made and entered into as of May 5, 2020, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (“Landlord”), and NKARTA, INC., a Delaware corporation (“Tenant”).
FIFTH AMENDMENT TO LEASELease • August 11th, 2022 • Nkarta, Inc. • Pharmaceutical preparations
This FIFTH AMENDMENT TO LEASE (this "Fifth Amendment") is made and entered into as of August 11, 2022 (the “Effective Date”), by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
FIRST AMENDMENT TO LEASELease • November 10th, 2021 • Nkarta, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of the date of last signature below, by and between HCP BTC, LLC, a Delaware limited company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
AMENDMENT NO. 1 TO OFFER LETTEROffer Letter • May 13th, 2021 • Nkarta, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 (this “Amendment”) is effective as of January 1, 2019, and is made to the Offer Letter of Employment, by and between Nkarta, Inc., a Delaware corporation (the “Company”), and Nadir A. Mahmood (“Mahmood”), dated April 2, 2018 (the “Offer Letter”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Offer Letter.
Notice of Grant of Director Stock Option and Terms and Conditions of Director Stock OptionDirector Stock Option Agreement • August 20th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • Delaware
Effective [___________] (the “Award Date”), you (the “Director”) have been granted a nonqualified stock option (the “Option”) to buy [________] shares1 of Common Stock of Nkarta, Inc. (the “Corporation”) at a price of $[_______] per share1 (the “Exercise Price”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • August 12th, 2021 • Nkarta, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AGREEMENT (this “Agreement”) is entered into as of May 5, 2021 (the “Effective Date”) by and between Nkarta, Inc., a corporation organized and existing under the laws of Delaware (“Nkarta”), and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.”
NKARTA, INC.Stock Option Agreement • June 19th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in the 2015 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 20th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • England and Wales
NATIONAL UNIVERSITY OF SINGAPORE, (Company Registration Number: 200604346E), a company limited by guarantee incorporated in Singapore, having its registered address at 21 Lower Kent Ridge Road, Singapore 119077 (“NUS”),
THIRD AMENDMENT TO LEASELease • May 11th, 2023 • Nkarta, Inc. • Pharmaceutical preparations
This THIRD AMENDMENT TO LEASE (this "Third Amendment") is made and entered into as of April 25, 2023, by and between HCP BTC, LLC, a Delaware limited company (“Landlord”), and NKARTA, INC., a Delaware corporation (“Tenant”).
Amendment No. 4 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • August 13th, 2024 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 4 to the Research Collaboration Agreement (the “Amendment”) is entered into as of May 2, 2024 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022, Amendment No. 2 to the Research Collaboration Agreement entered into as of March 8, 2023, and Amendment No. 3 to the Research Collaboration Agreement entered into as of April 3, 2024 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • October 5th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • California
This Separation and Release Agreement (this “Agreement”) is made and entered into this 2nd day of October 2020 (the “Effective Date”), by and between Nkarta, Inc., a Delaware corporation (the “Company”), and Matthew Plunkett (“Individual”).
Amendment No. 1 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • May 12th, 2022 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Research Collaboration Agreement (the “Amendment”) is entered into as of May 4, 2022 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR, as supplemented (the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
THIRD AMENDMENT TO LEASELease • March 25th, 2021 • Nkarta, Inc. • Pharmaceutical preparations
This THIRD AMENDMENT TO LEASE (this "Third Amendment") is made and entered into as of January 14, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
SEVERANCE AGREEMENTSeverance Agreement • January 13th, 2021 • Nkarta, Inc. • Pharmaceutical preparations • California
THIS SEVERANCE AGREEMENT (this “Agreement”) is made and entered into this _____ day of _________ 2021 (the “Effective Date”), by and between Nkarta, Inc., a Delaware corporation (the “Company”), and [______________] (the “Executive”).
Amendment No. 2 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • May 11th, 2023 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Research Collaboration Agreement (the “Amendment”) is entered into as of March 8, 2023 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
FOURTH AMENDMENT TO LEASELease • August 10th, 2023 • Nkarta, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of the date of last signature below, by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant").
